Updated Visante study shows MAC legislation may increase generic drug prices

Findings of an updated Visante study prepared for the Pharmaceutical Care Management Association revealed proposed Maximum Allowable Cost (MAC) restriction could increase the costs of affected generic drugs by up to 56 percent.

Visante’s analysis of more than 800 drugs that would likely be affected by legislation restricting MACs revealed that restrictions could increase generic drug costs by 31 to 56 percent. States that restrict MACs could see a 2 percent increase in drug costs. Additionally, if MAC legislation was passed throughout the nation, generic drug spending could increase by up to $6.2 billion a year.

A MAC is the maximum amount that a health plan will reimburse a pharmacy for a certain generic prescription. Pharmacies that are in a plan’s network must accept the MACs that the plan has set. It is a savings tool that large employers, Medicaid, Medicare and other plans use to prevent overpayments for generic medication.

Generic drugs sometimes have inflated manufacturer's list prices that do not show how much a pharmacy actually paid for the product. Without MACs, pharmacies could make extra profit by selling generic drugs at the maximum list price.

According to analysis by the Health and Human Services' Office of Inspector General, MACs are very efficient in containing the price of Medicaid drugs. 

Want to get notified whenever we write about Pharmaceutical Care Management Association ?
Next time we write about Pharmaceutical Care Management Association, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Pharmaceutical Care Management Association 325 7th St NW Washington, DC - 20004